Human Endogenous Retrovirus K in Cancer: A Potential Biomarker and Immunotherapeutic Target.
Gislaine CurtyJez L MarstonMiguel de MulderFabio E LealDouglas F NixonMarcelo Alves SoaresPublished in: Viruses (2020)
In diseases where epigenetic mechanisms are changed, such as cancer, many genes show altered gene expression and inhibited genes become activated. Human endogenous retrovirus type K (HERV-K) expression is usually inhibited in normal cells from healthy adults. In tumor cells, however, HERV-K mRNA expression has been frequently documented to increase. Importantly, HERV-K-derived proteins can act as tumor-specific antigens, a class of neoantigens, and induce immune responses in different types of cancer. In this review, we describe the function of the HERV-K HML-2 subtype in carcinogenesis as biomarkers, and their potential as targets for cancer immunotherapy.